Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095433
Status:
COMPLETED
Last Update Posted:
2014-03-26
First Post:
2004-11-04
Brief Title:
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration AMD
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase III rhuFab V2 Study
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III open-label multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization CNV secondary to AMD who have completed the treatment phase of a Genentech sponsored Phase I or Phase III ranibizumab protocol FVF1770g FVF2128g or FVF2425g
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None